Jun 29, 2021 / 02:00PM GMT
Operator
[Good morning, and welcome to day 2 of Taysha Gene Therapies R&D Day].(Operator Instructions) Today, the company will present new data and updates for its pipeline candidates in SURF1-associated Leigh syndrome, SLC13A5 deficiency, SLC6A1 haploinsufficiency, adult polyglucasan body disease or APBD, Lafora disease, tauopathies and Angelman syndrome.
Joining the call today is RA Session II, Taysha's President, Founder and Chief Executive Officer; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Dr. Steven Gray, Chief Scientific Adviser and Associate Professor in the Department of Pediatrics at UT Southwestern; Dr. Berge Minassian, Chief Medical Adviser and Division Chief of Pediatric Neurology at UT Southwestern; Dr. Rachel Bailey, Associate Professor in the Department of Pediatrics at UT Southwestern; and Dr. Kimberly Goodspeed, Assistant Professor in the Department of Pediatrics, Neurology and Psychiatry at UT Southwestern; Dr. Ryan Butler, Assistant Professor in the Department of Psychiatry and Pediatrics at UT Southwestern will join the Q&A session for Angelman syndrome.
Taysha Gene Therapies Inc R&D Day 2 Transcript
Jun 29, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers